Sofia Campelos

Dr. Sofia Campelos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Catarina EloyCatarina Eloy
Catarina Eloy
JVJoão Vale
João Vale
MCMónica Curado
Mónica Curado
APAntónio Polónia
António Polónia
SCSofia Campelos
Sofia Campelos
MSManuel Sobrinho-Simões
Manuel Sobrinho-Simões
The advantages of the digital methodology are well known. In this paper, we provide a detailed description of the process for the digital transformation of the pathology laboratory at IPATIMUP, the major modifications that operate throughout the processing pipeline, and the advantages of its implementation. The model of digital workflow implementation at IPATIMUP demonstrates that careful planning and adoption of simple measures related to time, space, and sample management can be adopted by any pathology laboratory to achieve higher quality and easy digital transformation.

29 May 2023 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Nelson FariaNelson Faria
Nelson Faria
SCSofia Campelos
Sofia Campelos
Vítor CarvalhoVítor Carvalho
Vítor Carvalho
Lung cancer is a leading cause of cancer-related deaths worldwide, and its diagnosis must be carried out as soon as possible to increase the survival rate. The development of computer-aided diagnosis systems can improve the accuracy of lung cancer diagnosis while reducing the workload of pathologists. The purpose of this study was to develop a learning algorithm (CancerDetecNN) to evaluate the presence or absence of tumor tissue in lung whole-slide images (WSIs) while reducing the computational cost. Three existing deep neural network models, including different versions of the CancerDetecNN algorithm, were trained and tested on datasets of tumor and non-tumor tiles extracted from lung WSIs. The fifth version of CancerDetecNN (CancerDetecNN Version 5) outperformed all existing convolutional neural network (CNN) models in the provided dataset, achieving higher precision (0.972), an area under the curve (AUC) of 0.923, and an F1-score of 0.897, while requiring 1 h and 51 min less for training than the best compared CNN model (ResNet-50). The results for CancerDetecNN Version 5 surpass the results of some architectures used in the literature, but the relatively small size and limited diversity of the dataset used in this study must be considered. This paper demonstrates the potential of CancerDetecNN Version 5 for improving lung cancer diagnosis since it is a dedicated model for lung cancer that leverages domain-specific knowledge and optimized architecture to capture unique characteristics and patterns in lung WSIs, potentially outperforming generic models in this domain and reducing the computational cost.

28 August 2025 in Information
Verified
Journal Article
Open access
PDF file
Nelson FariaNelson Faria
Nelson Faria
SCSofia Campelos
Sofia Campelos
Vítor CarvalhoVítor Carvalho
Vítor Carvalho
The growing adoption of deep learning (DL) in early-stage cancer diagnosis has demonstrated remarkable performance across multiple imaging tasks. Yet, the lack of transparency in these models (“black-box” problem) limits their adoption in clinical environments. This study proposes a methodological framework for developing interpretable DL models to support the early histopathological diagnosis of lung cancer, with a focus on adenocarcinoma and squamous cell carcinoma. The approach leverages publicly available datasets (TCGA-LUAD, TCGA-LUSC, LC25000) and employs high-performing architectures such as EfficientNet, along with post hoc explainability techniques including Grad-CAM and SHAP. Data will be pre-processed and sampled using stratified purposeful strategies to ensure diversity and balance across subtypes and stages. Model evaluation will combine standard performance metrics with clinician feedback and the spatial alignment of visual explanations with ground-truth annotations. While implementation remains a future step, this paper proposes a methodological framework designed to guide the development of DL systems that are not only accurate but also interpretable and clinically meaningful.

18 September 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
GAGabriela M Almeida
Gabriela M Almeida
CPCarla Pereira
Carla Pereira
JPJi-Hyeon Park
Ji-Hyeon Park
CLCarolina Lemos
Carolina Lemos
SCSofia Campelos
Sofia Campelos
COCarla Oliveira
Carla Oliveira
In gastric cancer (GC), biomarkers that define prognosis and predict treatment response remain scarce. We hypothesized that the extent of CD44v6 membranous tumor expression could predict prognosis and therapy response in GC patients. Two GC surgical cohorts, from Portugal and South Korea (n = 964), were characterized for the extension of CD44v6 membranous immuno-expression, clinicopathological features, patient survival, and therapy response. The value of CD44v6 expression in predicting response to treatment and its impact on prognosis was determined. High CD44v6 expression was associated with invasive features (perineural invasion and depth of invasion) in both cohorts and with worse survival in the Portuguese GC cohort (HR 1.461; 95% confidence interval 1.002–2.131). Patients with high CD44v6 tumor expression benefited from conventional chemotherapy in addition to surgery (p < 0.05), particularly those with heterogeneous CD44v6-positive and -negative populations (CD44v6_3+) (p < 0.007 and p < 0.009). Our study is the first to identify CD44v6 high membranous expression as a potential predictive marker of response to conventional treatment, but it does not clarify CD44v6 prognostic value in GC. Importantly, our data support selection of GC patients with high CD44v6-expressing tumors for conventional chemotherapy in addition to surgery. These findings will allow better stratification of GC patients for treatment, potentially improving their overall survival.

19 September 2023 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
Catarina EloyCatarina Eloy
Catarina Eloy
BNBeatriz Neves
Beatriz Neves
JVJoão Vale
João Vale
SCSofia Campelos
Sofia Campelos
MCMónica Curado
Mónica Curado
APAntónio Polónia
António Polónia

12 September 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Micaela AlmeidaMicaela Almeida
Micaela Almeida
VCVitor Manuel Caeiro
Vitor Manuel Caeiro
DCDiana Costa
Diana Costa
LSLara Silva
Lara Silva
CSCíntia Sousa
Cíntia Sousa
LGLuiza Granadeiro
Luiza Granadeiro
Background: Human papillomavirus (HPV), a leading cause of cervical cancer, is present in most cases of the disease and ranks as the fourth most common cancer in women globally. Among the HPV types, fourteen (HPV 16/18/31/33/35/39/45/51/52/56/58/59/66/68) are recognized as high-risk (hrHPV), each with varying levels of oncogenic potential. Detecting and genotyping these hrHPV types in cervical lesions is crucial, requiring the development of new diagnostic methods. Methods: This study focuses on a retrospective analysis conducted on 44 women from the Cova da Beira Local Health Unit. We used the Anyplex™ II hrHPV Detection kit for hrHPV genotyping from paraffin-embedded cervical tissue samples. Results: hrHPV types were identified in 38 out of the 44 women. Genotyping revealed HPV-16 (55.3%), HPV-18/39/56/58/59 (5.3%), HPV-31 (21.1%), HPV-35 (7.9%), HPV-51/66 (2.6%), and HPV-52 (10.5%). Conclusions: This study demonstrates that the Anyplex™ II hrHPV Detection kit, originally designed for cervical cancer screening, is also effective for hrHPV genotyping in histological analyses. This methodology offers a simpler and more cost-effective approach for cervical cancer risk stratification. Its implementation in clinical practice could enhance the detection of hrHPV in cervical lesions, thereby contributing to more precise diagnoses and potentially more informed treatment strategies.